Stammdaten
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Unternehmen & Branche
| Name | Acumen Pharmaceuticals, Inc. |
|---|---|
| Ticker | ABOS |
| CIK | 0001576885 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 150,2 Mio. USD |
| Beta | 0,34 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -121,335,000 | -2.00 | 122,833,000 | 70,430,000 | |
| 2025-09-30 | 10-Q | -26,451,000 | -0.44 | 142,221,000 | 93,173,000 | |
| 2025-06-30 | 10-Q | -40,950,000 | -0.68 | 171,897,000 | 117,077,000 | |
| 2025-03-31 | 10-Q | -28,796,000 | -0.48 | 204,478,000 | 155,521,000 | |
| 2024-12-31 | 10-K | -102,329,000 | -1.71 | 238,992,000 | 181,816,000 | |
| 2024-09-30 | 10-Q | -29,765,000 | -0.50 | 266,975,000 | 217,202,000 | |
| 2024-06-30 | 10-Q | -20,537,000 | -0.34 | 288,913,000 | 243,947,000 | |
| 2024-03-31 | 10-Q | -14,873,000 | -0.25 | 300,967,000 | 262,034,000 | |
| 2023-12-31 | 10-K | -52,371,000 | -1.08 | 310,125,000 | 266,973,000 | |
| 2023-09-30 | 10-Q | -12,957,000 | -0.24 | 286,371,000 | 280,273,000 | |
| 2023-06-30 | 10-Q | -11,610,000 | -0.28 | 177,405,000 | 168,874,000 | |
| 2023-03-31 | 10-Q | -11,307,000 | -0.28 | 187,864,000 | 179,085,000 | |
| 2022-12-31 | 10-K | -42,856,000 | -1.06 | 196,587,000 | 188,775,000 | |
| 2022-09-30 | 10-Q | -10,710,000 | -0.26 | 203,264,000 | 196,651,000 | |
| 2022-06-30 | 10-Q | -10,151,000 | -0.25 | 211,678,000 | 206,519,000 | |
| 2022-03-31 | 10-Q | -9,129,000 | -0.23 | 220,087,000 | 216,089,000 | |
| 2021-12-31 | 10-K | -100,606,000 | -5.02 | 230,330,000 | 225,183,000 | |
| 2021-09-30 | 10-Q | -3,902,000 | -0.10 | 234,849,000 | 233,360,000 | |
| 2021-06-30 | 10-Q | -61,358,000 | -141.93 | 72,943,000 | -106,079,000 | |
| 2021-03-31 | 10-Q | -26,997,000 | -45,462,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.